Pharmacy Benefit Discounts Continue, But At Slower Pace
11 Agosto 2010 - 4:11PM
Dow Jones News
The U.S.'s big pharmacy benefit managers continue to offer
clients better deals this year as they compete for business, but
they don't appear to be sliding into a frenzy of unreasonable
pricing.
In the current "selling season," when PBMs look to sign
customers for the following year, discounts on new contracts have
deepened by one or two percentage points, on average, from a year
ago. While PBMs are still lowering their pricing, the pace is
slower than a year ago, when PBMs were willing to expand discounts
by as much as five percentage points, according to benefit
consultants who guide employers on choosing a vendor.
It is unclear how the lower prices will impact margins next year
at large PBMs like Medco Health Solutions Inc. (MHS), CVS Caremark
Corp. (CVS) and Express Scripts Inc. (ESRX). The increased use of
generic drugs, which lowers PBMs' costs, allows them to be more
flexible with prices. That accounts for some of the discount.
The big PBMs have reported lower margins this year, citing a
variety of reasons. Medco, though, specifically mentioned lower
pricing on renewing contracts, among other items.
PBMs "are taking a little bit of a hit to margin, not much, but
they are taking one," said Michael Jacobs, national clinical
practice leader at Xerox Corp.'s (XRX) Buck Consultants. He said
the companies have ways of making up elsewhere for client discounts
-- through greater operating efficiency, cost-shifting to members
or raising prices on other drugs.
PBMs handle prescription-drug benefits for employers and health
plans, negotiating pricing -- including rebates and discounts --
with drug makers and pharmacies. They also run their own profitable
mail-order pharmacies. The competitive industry has come under
increasing pressure to pass along rebates and discounts and improve
transparency.
Currently, the industry is engaged in its selling season for
2011 contracts, with billions of dollars in new and renewing
business up for grabs or already won.
"Pricing got more competitive this year," said Kristin Begley,
national pharmacy practice leader at benefits consultant Hewitt
Associates Inc. (HEW), who didn't see much switching among her
large, national clients, many of which contract with CVS Caremark
or Medco.
Rebates got better, and there were "overall better deals across
the board," Begley said. Also, she said, most Hewitt client bids
this year required full transparency on pricing structure, with
PBMs earning an administrative fee and making money on mail-order
while forgoing a margin on drugs dispensed at retail.
PBMs are offering clients better discounts on generic drugs,
said David Dross, partner and managed pharmacy practice leader at
the Marsh & McLennan Cos. (MMC) Mercer LLC consulting business.
Dross added that he has seen some bigger discounts for brand-name
drugs as well, although underlying costs on branded drugs generally
are increasing.
PBM managements have indicated pricing trends are rational, even
though a Sanford C. Bernstein & Co. employer survey earlier
this summer suggested a "notable deterioration of the PBM pricing
environment," with more than 40% of respondents noting a decrease
in prices.
"Our pricing disciplines have been applied consistently for the
past several years as well as going forward to 2011," Medco
spokesman Lowell Weiner said. Medco CEO David Snow Jr., who earlier
this year noted instances of aggressive pricing, said last month
that he was feeling more comfortable with the competitive
marketplace.
Meanwhile, Express Scripts CEO George Paz has said that while
"pricing has always been extremely aggressive," the company uses
clinical tools to help drive out costs.
Per Lofberg, who heads CVS Caremark's PBM operation, recently
told analysts that pricing is "intensely competitive like it always
... has been, but it's fundamentally very similar to the past. When
plans go out for bid, they are always looking for better economics,
and that's a very important part of the negotiations."
John Malley, eastern region pharmacy practice leader at Towers
Watson & Co. (TW), said PBM pricing isn't irrational, although
it is changing in structure so that players offer better pricing
without necessarily losing margin.
"So more simply put, the level of discounts off prescription
drugs is not that different between last year and this year, but
the overall value of this year's deals, all in, is better than last
year" for the clients, Malley said.
Pricing will become less important a competitive factor as more
drugs go generic, Mercer's Dross predicted. PBMs already are trying
to differentiate their clinical offerings, which aim to close gaps
in care, customize prescriptions based on genetics and improve
compliance to produce better health outcomes and lower costs.
-By Dinah Wisenberg Brin, Dow Jones Newswires, 215-656-8285;
dinah.brin@dowjones.com
Hewitt Assoc A (NYSE:HEW)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Hewitt Assoc A (NYSE:HEW)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024